查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018082

抗病毒療法市場：2026-2032年全球市場預測（依疾病、藥物分類、給藥途徑、治療方法及分銷管道分類）

Antiviral Therapeutics Market by Disease Type, Drug Class, Route Of Administration, Therapy Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，抗病毒療法市場價值將達到 882.9 億美元，到 2026 年將成長至 950.6 億美元，到 2032 年將達到 1,570.2 億美元，複合年成長率為 8.57%。

主要市場統計數據
基準年 2025 882.9億美元
預計年份：2026年 950.6億美元
預測年份 2032 1570.2億美元
複合年成長率 (%) 8.57%

這份決策者的綜合指南整體情況了現代抗病毒療法，整合了科學進步、監管現實和商業策略。

目前抗病毒療法的發展正處於科學發現加速、公共衛生期望不斷變化以及商業性競爭日益激烈的交匯點。近年來，新型治療方法和給藥技術已從概念驗證（PoC）階段邁向臨床實踐，這為研發者、生產者和支付者創造了一個更複雜但也充滿機會的環境。如今，相關利益者必須在治療方法創新與成本壓力、供應鏈脆弱性以及主要全球司法管轄區不斷變化的監管標準之間取得平衡。

平台技術、監管創新和生產靈活性的整合如何從根本上改變抗病毒藥物的發現、開發和供應。

一系列變革正在重塑抗病毒藥物的發現、開發和遞送方式。在緊急公共衛生危機中已證明其適用性的平台技術，如今正被重新應用於更廣泛的病毒靶點，從而能夠快速識別先導化合物並最佳化開發路徑。同時，單株抗體工程技術的成熟和宿主導向療法的精細化，正將治療選擇拓展到傳統小分子抑制劑之外。

本研究評估了近期美國關稅措施對抗病毒藥物的供應鏈、採購和生產決策的累積營運和策略影響。

2025年實施的政策變革和貿易措施為全球抗病毒藥物供應鏈和籌資策略帶來了新的不穩定性。影響關鍵原料和成品藥的關稅調整使跨境採購的成本計算變得複雜，迫使企業重新評估其供應商網路和庫存策略。為此，許多企業正在加快在地化生產、擴大契約製造夥伴關係關係以及實現活性成分（API）供應商多元化，以降低對單一來源的依賴風險。

將疾病標靶、藥物分類、給藥途徑、分銷管道和治療目標與臨床和商業性決策聯繫起來的策略性細分洞察。

基於細分市場的分析揭示了不同治療標靶和治療方法的不同趨勢，這些趨勢應體現在產品組合和商業化選擇中。疾病特異性考量因素差異顯著。對於急性呼吸道病毒，需要快速起效和易於給藥；而對於丙型肝炎和愛滋病等慢性感染疾病，則優先考慮持續性病毒抑制、提高用藥依從性和抗藥性管理。巨細胞病毒和呼吸道融合細胞病毒等新發和再發病毒標靶需要專門的臨床開發方法，而標靶生物製藥和預防策略通常有效。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和市場進入挑戰影響著開發、製造和商業化選擇。

區域差異造就了獨特的營運和法規環境，進而影響研發管線的優先排序和上市時間策略。在美洲，完善的臨床試驗基礎設施、大量的公共和私人研發投入以及複雜的醫保報銷環境，都要求提供證據包，證明新療法相對於現有標準治療方法具有療效和價值。儘管該地區的監管路徑也包括針對高優先級治療方法的早期准入計劃，但相關利益者仍需仔細審查定價，並應對支付主導的准入限制。

本文介紹了企業層面的挑戰，展示了主要製藥網路、專業生物技術公司和製造合作夥伴如何合作推動抗病毒藥物的創新和商業化。

這些公司的策略揭示了一個兩極化的生態系統：大規模一體化製藥公司和靈活的生物技術公司各自追求互補的創新路徑。成熟的跨國公司利用其深厚的監管專長、廣泛的生產網路和全球商業性影響力，推動後期專案並擴大複雜生物製藥規模。同時，高度專業化的生物技術公司專注於高影響力科學、罕見或孤兒病毒靶點以及創新治療方法，並日益依賴戰略夥伴關係、授權合約和基於里程碑的合作來加速臨床開發並資金籌措。

為高階主管提供切實可行的跨職能建議，以增強抗病毒療法價值鏈的韌性，加速產品上市速度，並最佳化商業化進程。

產業領導者應採取整合策略，將科學差異化、營運韌性和市場導向的證據產生結合。首先，應實現關鍵原料和生物製藥成分供應商網路的多元化，同時建立雙源協議和安全庫存政策，以降低供應中斷風險。此外，還應投資於靈活且地理分散的生產能力，包括與能夠靈活切換不同治療方法的契約製造製造商建立合作關係。

為了確保獲得可操作的見解，我們採用了一種嚴謹的多方面研究途徑，結合了與主要相關利益者的訪談、臨床和監管審查、供應鏈映射以及專家的反覆檢驗。

本研究途徑結合了多種一手和二手調查方法，以確保研究結果的可靠性和可重複性。一手研究包括對臨床研究人員、醫院和專科診所採購經理、生產企業高管以及法規事務專家進行結構化訪談。為了補充這些定性信息，研究人員系統地查閱了臨床試驗註冊數據、同行評審文獻、專利和監管申報文件，以梳理發展軌跡並識別新興的科學主題。

將策略洞察融入創新、營運韌性和市場相關證據的生成，從而推動抗病毒療法的長期成功。

抗病毒療法正處於一個動態的轉折點，技術創新、監管進步和市場力量在此交匯，既帶來了機遇，也帶來了挑戰。科學進步不斷拓展治療選擇，而營運和政策的變革則要求加強供應鏈韌性，並建立以市場為導向的證據體系。能夠將前沿科學與靈活的生產能力、高度適應性的臨床策略以及針對不同區域最佳化的商業化方案相結合的機構，才能最終取得成功。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 抗病毒治療市場：依疾病類型分類

  • 2019冠狀病毒感染疾病
  • 巨細胞病毒
  • C型肝炎
  • 皰疹
  • HIV
  • 流感
  • 呼吸道融合細胞病毒

第9章：抗病毒治療藥物市場：依藥物類別分類

  • 融合抑制劑
  • 整合酶抑制劑
  • 干擾素
  • 單株抗體
  • 神經氨酸酶抑制劑
  • NNRTI
  • NRTI
  • 聚合酵素抑制劑
  • 蛋白酶抑制劑

第10章：抗病毒治療藥物市場：依給藥途徑分類

  • 吸入
  • 注射藥物
  • 口服
  • 外用

第11章 依治療方法分類的抗病毒治療市場

  • 預防
  • 治療

第12章：抗病毒治療藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科診所

第13章 抗病毒治療藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：抗病毒治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 抗病毒治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國抗病毒治療市場

第17章：中國抗病毒治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Alkem Laboratories Limited
  • AstraZeneca PLC
  • Atea Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Cocrystal Pharma, Inc.
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Syngene International Limited
  • Takeda Pharmaceutical Company Limited
  • Themis Medicare Ltd.
  • Venatorx Pharmaceuticals, Inc.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-037F3DB2591D

The Antiviral Therapeutics Market was valued at USD 88.29 billion in 2025 and is projected to grow to USD 95.06 billion in 2026, with a CAGR of 8.57%, reaching USD 157.02 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 88.29 billion
Estimated Year [2026] USD 95.06 billion
Forecast Year [2032] USD 157.02 billion
CAGR (%) 8.57%

Comprehensive orientation to the modern antiviral therapeutics landscape that integrates scientific progress, regulatory realities, and commercial strategy for decision-makers

The antiviral therapeutics landscape stands at the confluence of accelerated scientific discovery, shifting public health expectations, and intensifying commercial competition. Recent years have seen novel modalities and delivery technologies transition from proof-of-concept to clinical reality, catalyzing a more complex but opportunity-rich environment for developers, manufacturers, and payers. Stakeholders must now reconcile therapeutic innovation with cost pressures, supply chain vulnerabilities, and evolving regulatory standards across key global jurisdictions.

As the pathogen spectrum broadens and the emphasis on pandemic preparedness grows, organizations must recalibrate their strategic priorities. Investments in broad-spectrum platforms, host-targeted approaches, and adaptive manufacturing have risen in prominence. At the same time, payers and procurement bodies increasingly scrutinize clinical value and real-world effectiveness, prompting sponsors to design evidence generation strategies that extend beyond pivotal trials. Consequently, leaders who integrate scientific rigor with commercial foresight and operational resilience will shape the next phase of antiviral therapeutics development and delivery.

How converging platform technologies, regulatory innovations, and manufacturing agility are fundamentally altering antiviral drug discovery, development, and delivery

A series of transformative shifts is reshaping how antiviral drugs are discovered, developed, and delivered. Platform technologies that proved adaptable during urgent public health crises are now being repurposed toward a wider range of viral targets, enabling faster lead identification and more agile development pathways. Simultaneously, the maturation of monoclonal antibody engineering and the refinement of host-directed therapies are expanding therapeutic options beyond traditional small-molecule inhibitors.

Digital capabilities and artificial intelligence have accelerated target discovery and optimized candidate selection, while modular and single-use manufacturing solutions are reducing lead times and increasing geographic flexibility. These scientific and operational changes are complemented by regulatory innovation, where expedited pathways and adaptive trial designs are facilitating conditional access for high unmet need indications. Taken together, these shifts underscore a landscape where technological convergence, regulatory agility, and manufacturing adaptability determine commercial success.

Assessing the cumulative operational and strategic consequences of recent United States tariff measures on antiviral supply chains, procurement, and manufacturing decisions

Policy changes and trade measures implemented in 2025 have introduced a new variable into global antiviral supply chains and procurement strategies. Tariff adjustments impacting key raw materials and finished pharmaceuticals have elevated the cost calculus for cross-border sourcing, prompting firms to re-evaluate supplier networks and inventory strategies. In response, many organizations have accelerated efforts to localize production, expand contract manufacturing partnerships, and diversify active pharmaceutical ingredient suppliers to mitigate single-source exposure.

Beyond immediate cost implications, tariffs have influenced long-term strategic choices. Sponsors and manufacturers have revisited site selection decisions for new facilities, factoring in tariff risk alongside labor, talent availability, and regulatory alignment. Procurement organizations in hospitals, retail pharmacies, and specialty clinics have adapted contracting approaches to include greater flexibility around supply guarantees and price escalators. Ultimately, the cumulative impact of trade measures has crystallized the need for resilient, multi-layered supply strategies that preserve continuity of care while maintaining commercial viability.

Strategic segmentation insights tying disease targets, drug classes, administration routes, distribution channels, and therapy objectives to clinical and commercial decision-making

Segmentation-driven analysis reveals differentiated dynamics across therapeutic targets and modalities that should inform portfolio and commercialization choices. Disease-specific considerations vary markedly: responses to acute respiratory viruses demand rapid onset and convenient administration, whereas chronic infections such as hepatitis C and HIV prioritize sustained viral suppression, adherence support, and resistance management. Emerging and re-emerging targets like cytomegalovirus and respiratory syncytial virus require specialized clinical development approaches and often benefit from targeted biologics or prophylactic strategies.

Drug-class distinctions influence development timelines and deployment. Small-molecule polymerase and protease inhibitors typically offer oral dosing advantages and established manufacturing footprints, while monoclonal antibodies and interferons frequently rely on injectable formats and complex biologics production. Fusion and integrase inhibitors, as well as nucleoside and non-nucleoside reverse transcriptase inhibitors, each carry distinct resistance profiles and combination therapy implications. Route of administration further shapes uptake and adherence: oral agents facilitate outpatient treatment and retail pharmacy distribution, injectable formulations often necessitate hospital or specialty clinic involvement, inhalation and topical options serve niche respiratory and localized indications, and delivery mode directly affects reimbursement pathways and patient preference.

Distribution-channel strategies must align with both product attributes and health system capabilities. Hospital pharmacies and specialty clinics play critical roles for parenteral biologics and complex therapeutics that require monitoring, whereas retail and online pharmacies expand access for oral antivirals and prophylactic products. Finally, the therapy objective-prophylaxis versus treatment-dictates clinical trial design, labeling nuances, and post-marketing evidence generation. Prophylactic products often emphasize population-level effectiveness and safety over extended periods, while therapeutic agents prioritize immediate clinical endpoints and resistance surveillance. Integrating these segmentation lenses enables targeted clinical development, tailored market access plans, and optimized commercial deployment.

Regional dynamics and market access imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape development, manufacturing, and commercialization choices

Regional variations create distinct operational and regulatory environments that influence pipeline prioritization and go-to-market tactics. In the Americas, robust clinical trial infrastructure, substantial public and private R&D investment, and a complex reimbursement landscape require evidence packages that demonstrate comparative effectiveness and value over existing standards. Regulatory pathways in this region also accommodate accelerated access mechanisms for high-priority therapies, but stakeholders must navigate pricing scrutiny and payer-driven utilization controls.

Europe, Middle East & Africa present heterogenous regulatory frameworks and procurement models, with some markets emphasizing centralized evaluation and others relying on national assessment and tendering processes. This diversity necessitates nuanced market access strategies that balance regional dossiers with country-level evidence and pricing flexibility. In Asia-Pacific, rapid adoption of innovative platforms, a growing biomanufacturing base, and expanding private and public healthcare investment create fertile ground for strategic partnerships and regional manufacturing hubs. Nevertheless, differences in regulatory timelines, intellectual property enforcement, and local clinical practice patterns require tailored commercialization roadmaps. Across all regions, cross-border trade measures, local production incentives, and digital health adoption will continue to shape supply chain design and market entry sequencing.

Company-level imperatives showing how large pharmaceutical networks, specialized biotechs, and manufacturing partners align to advance antiviral innovation and commercialization

Company strategies reveal a bifurcated ecosystem where large integrated pharmaceutical firms and nimble biotechs pursue complementary pathways to innovation. Established multinationals leverage deep regulatory expertise, broad manufacturing networks, and global commercial reach to advance late-stage programs and scale complex biologics. In parallel, specialized biotechs focus on high-impact science, rare or orphan viral targets, and disruptive modalities, increasingly relying on strategic alliances, licensing arrangements, and milestone-driven collaborations to accelerate clinical development and access capital.

Contract development and manufacturing organizations have become pivotal ecosystem partners, enabling rapid scale-up and geographic diversification without the fixed-cost burden of new facilities. In addition, novel entrants specializing in delivery technologies, diagnostics, and data-driven clinical optimization are reshaping how companies design value propositions. Across the competitive landscape, successful organizations align scientific differentiation with pragmatic commercialization plans, prioritize durable manufacturing relationships, and commit to post-approval evidence generation that supports adoption in diverse healthcare systems.

Practical, cross-functional recommendations for executives to enhance resilience, accelerate access, and optimize commercialization across the antiviral therapeutic value chain

Industry leaders should adopt integrated strategies that combine scientific differentiation with operational resilience and market-focused evidence generation. First, diversify supplier networks for key raw materials and biologics components while establishing dual-source agreements and safety-stock policies to reduce disruption risk. Simultaneously, invest in flexible and geographically distributed manufacturing capacity, including partnerships with contract manufacturers that can pivot across modalities.

Second, prioritize platform technologies and combination approaches that address resistance and broaden the therapeutic window, while designing clinical programs with real-world endpoints and adaptive elements to support accelerated access. Third, align distribution strategies with product profiles by optimizing channels for adherence, access, and monitoring; for instance, pair oral therapies with online pharmacy programs and digital adherence tools, and route injectable biologics through specialty clinics with integrated patient support. Fourth, create pricing and contracting frameworks that reflect value over the product lifecycle, incorporate outcomes-based elements where feasible, and anticipate payer requirements across regions. Finally, strengthen cross-functional collaborations-linking R&D, regulatory, manufacturing, and commercial teams-to ensure that development decisions incorporate downstream deployment realities and that evidence strategies support sustainable uptake.

Rigorous multi-method research approach blending primary stakeholder interviews, clinical and regulatory review, supply chain mapping, and iterative expert validation to ensure actionable insights

The research approach combined multi-modal primary and secondary methods to ensure robust, reproducible insights. Primary engagements included structured interviews with clinical investigators, procurement leaders in hospitals and specialty clinics, manufacturing executives, and regulatory affairs specialists. These qualitative inputs were complemented by systematic reviews of clinical trial registries, peer-reviewed literature, patents, and regulatory filings to map development trajectories and identify emergent scientific themes.

To validate findings, the analysis incorporated supply chain mapping exercises, case studies of recent program launches, and triangulation of technical data with stakeholder perspectives. Quality controls included cross-validation between interview outputs and documentary evidence, iterative expert review cycles, and sensitivity checks on strategic implications. The result is a methodology that balances depth of insight with transparency of evidence sources and that supports pragmatic recommendations for decision-makers navigating antiviral therapeutic development and commercialization.

Synthesis of strategic implications where innovation, operational resilience, and market-aligned evidence generation determine long-term success in antiviral therapeutics

Antiviral therapeutics occupy a dynamic juncture where technological innovation, regulatory evolution, and market forces converge to create both opportunity and complexity. Scientific advances are expanding the therapeutic toolkit, while operational and policy shifts demand greater supply chain resilience and market-focused evidence generation. Success will favor organizations that can integrate cutting-edge science with flexible manufacturing, adaptive clinical strategies, and regionally tailored commercialization plans.

Looking ahead, the most effective programs will be those that anticipate resistance dynamics, prioritize patient-centric delivery models, and establish durable partnerships across manufacturing and distribution networks. By aligning scientific ambition with pragmatic execution, stakeholders can accelerate the translation of laboratory breakthroughs into therapies that deliver measurable clinical and public health benefits.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiviral Therapeutics Market, by Disease Type

  • 8.1. Covid-19
  • 8.2. Cytomegalovirus
  • 8.3. Hepatitis C
  • 8.4. Herpes
  • 8.5. Hiv
  • 8.6. Influenza
  • 8.7. Respiratory Syncytial Virus

9. Antiviral Therapeutics Market, by Drug Class

  • 9.1. Fusion Inhibitors
  • 9.2. Integrase Inhibitors
  • 9.3. Interferons
  • 9.4. Monoclonal Antibodies
  • 9.5. Neuraminidase Inhibitors
  • 9.6. Nnrtis
  • 9.7. Nrtis
  • 9.8. Polymerase Inhibitors
  • 9.9. Protease Inhibitors

10. Antiviral Therapeutics Market, by Route Of Administration

  • 10.1. Inhalation
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Topical

11. Antiviral Therapeutics Market, by Therapy Type

  • 11.1. Prophylaxis
  • 11.2. Treatment

12. Antiviral Therapeutics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy
  • 12.4. Specialty Clinics

13. Antiviral Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiviral Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiviral Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antiviral Therapeutics Market

17. China Antiviral Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. Alkem Laboratories Limited
  • 18.8. AstraZeneca PLC
  • 18.9. Atea Pharmaceuticals, Inc.
  • 18.10. Aurobindo Pharma Limited
  • 18.11. Bristol-Myers Squibb Company
  • 18.12. Cipla Ltd.
  • 18.13. Cocrystal Pharma, Inc.
  • 18.14. Daiichi Sankyo Company, Ltd.
  • 18.15. Dr. Reddy's Laboratories Ltd.
  • 18.16. Eli Lilly and Company
  • 18.17. F. Hoffmann-La Roche Ltd.
  • 18.18. Gilead Sciences, Inc.
  • 18.19. GlaxoSmithKline plc
  • 18.20. Hetero Labs Limited
  • 18.21. Johnson & Johnson Services Inc.
  • 18.22. Merck & Co., Inc.
  • 18.23. Novartis AG
  • 18.24. Pfizer Inc.
  • 18.25. Sanofi S.A.
  • 18.26. Sun Pharmaceutical Industries Limited
  • 18.27. Syngene International Limited
  • 18.28. Takeda Pharmaceutical Company Limited
  • 18.29. Themis Medicare Ltd.
  • 18.30. Venatorx Pharmaceuticals, Inc.
  • 18.31. Viatris Inc.
  • 18.32. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COVID-19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY CYTOMEGALOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NNRTIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NRTIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY POLYMERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)